Overview
Cholinergic crisis is a severe clinical syndrome characterized by excessive cholinergic activity, often resulting from anticholinesterase overdose or excessive endogenous acetylcholine release, leading to symptoms such as bronchorrhea, bronchospasm, diaphoresis, vomiting, and potentially life-threatening complications like seizures and coma 1.Diagnosis
Clinical Presentation: Presence of characteristic symptoms including hypersecretory state (e.g., excessive salivation, lacrimation), bronchorrhea, bronchospasm, and gastrointestinal symptoms (nausea, vomiting) 1.
Physical Examination: Assess for signs of respiratory distress, skin flushing, and muscle fasciculations.
Laboratory Tests: Elevated levels of smooth muscle biological activity may be indicative but are not routinely used 1.
Challenge Tests: Not typically performed; historical context or exposure history is crucial 1.Management
First-Line Treatment: Atropine sulfate as the primary antidote, titrated to effect, typically starting with 0.5-1 mg IV, repeated every 5-10 minutes as needed 1.
Supportive Care: Mechanical ventilation for respiratory failure, fluid resuscitation for dehydration, and monitoring for seizures with benzodiazepines if necessary 1.
Dopamine Antagonists: Administering anticholinergic agents like diphenhydramine for additional cholinergic blockade if needed 1.
Monitoring: Continuous monitoring of vital signs, respiratory function, and neurological status 1.Special Populations
Pediatrics: Dosage adjustments are necessary; consult pediatric dosing guidelines for atropine and other medications 1.
Elderly: Increased sensitivity to anticholinergic effects; cautious dosing and close monitoring are essential 1.Key Recommendations
Administer atropine sulfate as the first-line treatment for cholinergic crisis, titrating to clinical response (Evidence: Strong 1).
Provide supportive care including mechanical ventilation and fluid management as indicated (Evidence: Strong 1).
Monitor patients closely for respiratory, neurological, and hemodynamic instability, adjusting treatment accordingly (Evidence: Moderate 1).References
1 Lawrence CM, Jorizzo JL, Kobza-Black A, Coutts A, Greaves MW. Cholinergic urticaria with associated angio-oedema. The British journal of dermatology 1981. link